Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
NRG Oncology
NRG Oncology
Ohio State University Comprehensive Cancer Center
Stanford University
Mayo Clinic
Eastern Cooperative Oncology Group
Emory University
Vanderbilt-Ingram Cancer Center
Emory University
Centre Henri Becquerel
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Emory University
University of Southern California
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Abramson Cancer Center at Penn Medicine
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
Virginia Commonwealth University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Cliniques universitaires Saint-Luc- Université Catholique de Louvain